GlassBury AI combines agentic patient matching with culturally sensitive community education to eliminate healthcare disparities. By pairing AI with expert-curated workshops, we build the trust necessary to connect underrepresented patients with life-changing clinical trials.

DNA, AI in Healthcare, Clinical Trials, FDA Corey Hubbafd DNA, AI in Healthcare, Clinical Trials, FDA Corey Hubbafd

The Sociogenomics Revolution

For generations, humanity has grappled with one of life's most profound questions: are we products of our genes or our upbringing? This "nature versus nurture" debate has fueled countless discussions, academic papers, and even political stances. On one side stand the "blank-slaters," who believe our environment is the primary sculptor of who we become. On the other, the "hereditarians" argue that our destiny is largely etched in our genetic code.

Read More

Battling Alzheimer's: A New Hope on the Horizon

Alzheimer's Disease. The very name evokes a sense of dread, a long, slow fading of memory, personality, and ultimately, life itself. It's a condition that not only devastates those who suffer from it but also places an immense emotional and physical burden on their families and caregivers. For years, the scientific and medical communities have been locked in a relentless battle against this formidable foe, striving to understand its origins, slow its progression, and ideally, find a cure.

Read More

A New Lens on Alzheimer's: How GE HealthCare's Vizamyl is Revolutionizing Diagnosis and Treatment Monitoring

Imagine peering into the intricate workings of the human brain, not just to see its structure, but to uncover the subtle whispers of a disease that gradually erodes memory, thought, and ultimately, identity. For decades, Alzheimer's disease has presented a formidable challenge, often diagnosed only after significant cognitive decline has set in, and the opportunity for early intervention has diminished. But a recent development, spearheaded by the U.S. Food and Drug Administration (FDA) and GE HealthCare

Read More

INmune Bio: Alzheimer’s Trial Results and Stock Shock

The recent news surrounding INmune Bio has sent ripples through the biotechnology investment world, causing the company's stock to plummet by over 50%. This dramatic drop wasn't due to a scandal or financial mismanagement, but rather the outcome of a clinical trial for their Alzheimer's disease drug, XPro.

Read More
FDA, Alzheimer's Prevention, NAMI Corey Hubbafd FDA, Alzheimer's Prevention, NAMI Corey Hubbafd

Integrated Primary Care: A Path to Better Mental Health

Integrating behavioral health into regular doctor's visits is a game-changer for how we think about and receive mental healthcare. Imagine going to your family doctor for a sore throat, and during that same visit, you can also talk to someone about feeling stressed or anxious. This idea, called Integrated Primary Care (IPC), aims to bring together physical and mental health services under one roof.

Read More
Zocalo Health, #FDA, NIH Corey Hubbafd Zocalo Health, #FDA, NIH Corey Hubbafd

Bridging the Gap: Understanding Digital Mental Health Tools in Everyday Healthcare

Mental health is a crucial part of our overall well-being, yet for many people, especially those in underserved communities, getting the right mental health care can be incredibly difficult. They might face numerous obstacles, like a lack of local specialists, high costs, or the stigma often associated with seeking mental health support. This is where Integrated Primary Care (IPC) settings come into play.

Read More

Triumphant Return: Judge Orders FDA to Restore Vital Clinical Trial Diversity Webpages, Empowering Health Equity!

It is a truly hopeful and significant development in the realm of healthcare and government transparency that a US District Judge has recently ordered the full reinstatement of crucial healthcare resources, including vital webpages dedicated to clinical trial diversity, by the US Food and Drug Administration (FDA) and the Department of Health and Human Services

Read More

Stay Steady, Stay Safe: The Ultimate Guide to Preventing Falls and Fractures as You Age

For many older adults, a simple everyday mishap—like slipping on a wet floor or tripping over a rug—can instantly become a life-altering event. Falls are not just common; they are a significant threat to long-term health, mobility, and independence. Every year, thousands of older adults experience broken bones due to falls.

Read More
Alzheimer's Research, FDA, AI and Pharma Corey Hubbafd Alzheimer's Research, FDA, AI and Pharma Corey Hubbafd

The $17 Billion Race: Why New Treatments for Alzheimer’s Disease Are Changing the Game

The fight against Alzheimer’s disease (AD) is entering a new, highly competitive phase, driven by recent scientific breakthroughs and a growing global market. While therapies targeting amyloid proteins have recently been validated, there remains a critical and ongoing unmet need for drugs that utilize alternative mechanisms of action. Experts are encouraged to see a broader range of therapeutic options emerging in the pipeline for patients.

Read More

A Simple Blood Test Revolutionizes Alzheimer's Care: Why Roche's FDA Greenlight Changes Everything

The landscape of Alzheimer’s disease diagnosis and treatment is on the cusp of a dramatic transformation, thanks to the recent US Food and Drug Administration (FDA) clearance of a novel blood-based test developed by Roche. This approval is not just another step in medical technology; it signifies a potential "care paradigm shift" by introducing a simple, accessible tool that can efficiently evaluate the risk of Alzheimer’s disease pathology, particularly in primary care settings.

Read More

Remote Relief: How Virtual Support Boosts Mood and Confidence for Families Facing Dementia

Dementia is a health crisis sweeping the globe. Experts estimate that roughly 50 million people worldwide are currently living with this condition. That enormous figure is expected to nearly double to 80 million by 2030 and potentially surpass 150 million by 2050. Alarmingly, a new dementia diagnosis happens every three seconds.

Read More

Decoding the Latest Alzheimer's Setback: Why J&J’s "Failed" Drug Trial is Actually a Hidden Victory for Brain Science

When we think about the fight against Alzheimer’s disease, we often picture a coordinated, unstoppable march toward a cure led by massive organizations like the National Institute on Aging and the Alzheimer's Association.

HealthTech, Dementia Diagnostics, NIH Corey Hubbafd HealthTech, Dementia Diagnostics, NIH Corey Hubbafd

The Missing Link in Alzheimer’s: How a Natural Brain Element Could Be the Key to Reversing Memory Loss

For over thirty years, Bruce Yankner has been at the very forefront of Alzheimer's research. From his early days first proving the devastating toxicity of amyloid plaques in the 1990s, to his current work uncovering the brain's hidden reliance on natural lithium, his scientific journey has been nothing short of remarkable. By finally explaining the elusive missing link

Read More

Beyond the Memory Trap: Simple Blood Tests, Subcut Injections, and Smart Care Tech are Rewriting the Alzheimer’s Story

Explore the latest 2026 Alzheimer’s research updates. Discover how simple blood tests, new home-injection trials, AI healthtech, and modern caregiving strategies are transforming memory care and hospice support.

Read More

Beyond the "Black Box": Why Trust is the Ultimate Data Moat in Clinical Trial Recruitment

In the high-stakes world of clinical research, fixed machine learning models face a silent, inevitable threat: drift. As clinical practices shift, lab equipment is recalibrated, and patient populations evolve, static algorithms slowly degrade in accuracy. At Glassbury, we recognize that a "black box" approach is insufficient for the long-term challenges of Alzheimer's disease and related CNS conditions

Read More